Cullinan Therapeutics, Inc. (CGEM) Deep Dive Video

Cullinan offers a cash-backed, catalyst-rich biotech opportunity where zipalertinib’s potential launch and CLN-978’s autoimmune optionality create highly asymmetric upside, balanced by significant clinical, regulatory, and dilution risk.